Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR3 | P22607 | 14/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 13/20 | 0.38 |
| ▸ | FGFR2 | P21802 | 12/20 | 0.38 |
| ▸ | FGFR4 | P22455 | 11/20 | 0.38 |
| ▸ | KDR | P35968 | 9/20 | 0.38 |
| ▸ | MIF | P14174 | 2/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.34 |
| ▸ | MET | P08581 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL368129 | 0.88 | MIF (0.40) | FGFR3FGFR1FGFR2FGFR4KDR | |
| SCHEMBL14915754 | 0.83 | PDE10A (0.38) | FGFR3FGFR1FGFR2PDE10AGRM4 | |
| SCHEMBL358892 | 0.82 | PDE10A (0.41) | FGFR3FGFR1FGFR2FGFR4KDR | |
| SCHEMBL368727 | 0.82 | MET (0.41) | GRM4MET | |
| SCHEMBL359817 | 0.82 | MET (0.40) | FGFR3FGFR1FGFR2FGFR4KDR | |
| SCHEMBL367900 | 0.81 | MET (0.39) | FGFR3FGFR1FGFR2KDRPDE10A | |
| SCHEMBL255618 | 0.80 | PDE10A (0.38) | FGFR3FGFR1FGFR2FGFR4KDR | |
| SCHEMBL360598 | 0.80 | PDE10A (0.38) | FGFR3FGFR1PDE10AMET | |
| SCHEMBL178094 | 0.80 | MET (0.44) | FGFR3FGFR1MET | |
| SCHEMBL367903 | 0.79 | MET (0.40) | FGFR3FGFR1FGFR2FGFR4PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2593107-A1 | TYROSINE KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2013-05-22 | — | — | EP | claimed |
| US-20130116231-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2013-05-09 | — | — | US | claimed |
| WO-2012009194-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-01-19 | — | — | WO | claimed |
| US-20130116231-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2013-05-09 | — | — | US | disclosed |
| US-20130116231-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2013-05-09 | — | — | US | disclosed |
| US-20130116231-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2013-05-09 | — | — | US | disclosed |
| WO-2012009194-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116231-A1 | TYROSINE KINASE INHIBITORS | ABL1, ERBB2, MET | FGFR3 199/4885FGFR1 58/4885FGFR2 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.